FOLLOWUS
A randomized controlled trial of adjunctive Bunchang Naoxintong Capsule (步长脑心通胶囊) versus maintenance dose clopidogrel in patients with CYP2C19*2 polymorphism
A randomized controlled trial of adjunctive Bunchang Naoxintong Capsule (步长脑心通胶囊) versus maintenance dose clopidogrel in patients with CYP2C19*2 polymorphism
- 中国结合医学杂志（英文版） 2014年20卷第12期 页码：894-902
- Affiliations：
Fujian Provincial Cardiovascular Disease Institute, Provincial Clinical College of Fujian Medical University,Fuzhou,China
- Author bio：
- Funds：Supported by the Provincial Natural Science Foundation of Fujian (No. 2011J0133) and the National Natural Science Foundation of China (No. 81373838)
DOI：10.1007/s11655-014-2023-z
中图分类号：纸质出版日期：2014，
网络出版日期：2014-11-27，
Scan for full text
Chen, H., Wu, Xy., Wu, Hx. et al. A randomized controlled trial of adjunctive Bunchang Naoxintong Capsule (步长脑心通胶囊) versus maintenance dose clopidogrel in patients with CYP2C19*2 polymorphism., Chin. J. Integr. Med. 20, 894–902 (2014). https://doi.org/10.1007/s11655-014-2023-z
Hui Chen, Xiao-ying Wu, Hong-xia Wu, et al. A randomized controlled trial of adjunctive Bunchang Naoxintong Capsule (步长脑心通胶囊) versus maintenance dose clopidogrel in patients with CYP2C19*2 polymorphism[J]. Chinese Journal of Integrative Medicine, 2014,20(12):894-902.
Chen, H., Wu, Xy., Wu, Hx. et al. A randomized controlled trial of adjunctive Bunchang Naoxintong Capsule (步长脑心通胶囊) versus maintenance dose clopidogrel in patients with CYP2C19*2 polymorphism., Chin. J. Integr. Med. 20, 894–902 (2014). https://doi.org/10.1007/s11655-014-2023-z DOI：
Hui Chen, Xiao-ying Wu, Hong-xia Wu, et al. A randomized controlled trial of adjunctive Bunchang Naoxintong Capsule (步长脑心通胶囊) versus maintenance dose clopidogrel in patients with CYP2C19*2 polymorphism[J]. Chinese Journal of Integrative Medicine, 2014,20(12):894-902. DOI： 10.1007/s11655-014-2023-z.
摘要
To determine the impact of adjunctive Buchang Naoxintong Capsule (步长脑心通胶囊
NXT) on dual antiplatelet therapy in patients with cytochrome P450 2C19*2 (CYP2C19*2) polymorphism undergoing percutaneous coronary intervention (PCI). Ninety patients with CYP2C19*2 polymorphism were enrolled
and their genotypes were confirmed by polymerase chain reaction (PCR). The patients were randomly assigned to receive either adjunctive NXT (triple group
45 cases) or dual antiplatelet therapy (dual group
45 cases) using a computer-generated randomization sequence and sealed envelopes. Platelet function was assessed at baseline and 7 days after treatment with conventional aggregometry. Subsequent major adverse cardiovascular events (MACE
including sudden cardiac arrest and acute coronary syndrome) were recorded during a 12-month follow-up. Baseline platelet function measurements were similar in both groups. After 7 days
percent inhibitions of maximum platelet aggregation and late platelet aggregation were significantly greater in the triple versus dual group (42.3%±16.0% vs. 20.8%±15.2%
P<0.01
and 54.7%±18.3% vs. 21.5%±29.2%
P<0.01
respectively). During the 12-month follow-up
the rate of subsequent MACE (6/45) was significantly lower in the triple group compared with the dual group (14/45; P<0.05). Adjunctive NXT to maintenance dose clopidogrel (75 g) could enhance the antiplatelet effect and decrease subsequent MACE in patients with the CYP2C19*2 polymorphism undergoing PCI.
Abstract
To determine the impact of adjunctive Buchang Naoxintong Capsule (步长脑心通胶囊
NXT) on dual antiplatelet therapy in patients with cytochrome P450 2C19*2 (CYP2C19*2) polymorphism undergoing percutaneous coronary intervention (PCI). Ninety patients with CYP2C19*2 polymorphism were enrolled
and their genotypes were confirmed by polymerase chain reaction (PCR). The patients were randomly assigned to receive either adjunctive NXT (triple group
45 cases) or dual antiplatelet therapy (dual group
45 cases) using a computer-generated randomization sequence and sealed envelopes. Platelet function was assessed at baseline and 7 days after treatment with conventional aggregometry. Subsequent major adverse cardiovascular events (MACE
including sudden cardiac arrest and acute coronary syndrome) were recorded during a 12-month follow-up. Baseline platelet function measurements were similar in both groups. After 7 days
percent inhibitions of maximum platelet aggregation and late platelet aggregation were significantly greater in the triple versus dual group (42.3%±16.0% vs. 20.8%±15.2%
P<0.01
and 54.7%±18.3% vs. 21.5%±29.2%
P<0.01
respectively). During the 12-month follow-up
the rate of subsequent MACE (6/45) was significantly lower in the triple group compared with the dual group (14/45; P<0.05). Adjunctive NXT to maintenance dose clopidogrel (75 g) could enhance the antiplatelet effect and decrease subsequent MACE in patients with the CYP2C19*2 polymorphism undergoing PCI.
关键词
PlateletCYP2C19*2 gene mutationBuchang Naoxintong Capsulemaintenance dose clopidogrelclinical prognosisChinese Medicinerandomized controlled trial
Keywords
PlateletCYP2C19*2 gene mutationBuchang Naoxintong Capsulemaintenance dose clopidogrelclinical prognosisChinese Medicinerandomized controlled trial
references
Mega, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 2009;119:2553–2560.
Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009;373:309–317.
Shuldiner AR, O’Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009;302:849–857.
Mega JL, Close SL, Wiviott SD. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009;360:354–362.
Luo HR, Poland RE, Lin KM, Wan YJ. Genetic polymorphism of cytochrome P450 2C19 in Mexican Americans: a cross-ethnic comparative study. Clin Pharmacol Ther 2006;80:33–40.
Man M, Farmen M, Dumaual C, Teng CH, Moser B, Irie S, et al. Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans. J Clin Pharmacol 2010;50:929–940.
Liu XL, Wang ZJ, Yang Q, Ge HL, Gao F, Liu YY, et al. Impact of CYP2C19 polymorphism and smoking on response to clopidogrel in patients with stable coronary artery disease. Chin Med J 2010;123:3178–3183.
Chen H, Yan W, Wu XY. Relationships of blood stasis syndrome, CYP2C19 gene polymorphism with clopidogrel resistance and post-PCI prognosis. Chin J Integr Tradit West Med (Chin) 2010;30:1245–1249.
Holmes DR Jr, Dehmer GJ, Kaul S, Leifer D, O’Gara PT, Stein CM. ACCF/AHA clopidogrel clinical alert: approaches to the FDA “boxed warning”: a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol 2010;56:321–341.
Jang JS, Cho KI, Jin HY, Seo JS, Yang TH, Kim DK, et al. Meta-analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel. Am J Cardiol 2012;110:502–508.
Fontana P, Senouf D, Mach F. Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C19 2 allele on clopidogrel responsiveness. Thromb Res 2008;121:463–468.
Angiolillo DJ, Shoemaker SB, Desai B, Yuan H, Charlton RK, Bernardo E, et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 2007;115:708–716.
Tavassoli N, Voisin S, Carrie D, Lapeyre-Mestre M, Galinier M, Montastruc JL, et al. High maintenance dosage of clopidogrel is associated with a reduced risk of stent thrombosis in clopidogrel-resistant patients. Am J Cardiovasc Drugs 2010;10:29–35.
Mega JL, Hochholzer W, Frelinger AL 3rd, Kluk MJ, Angiolillo DJ, Kereiakes DJ, et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA 2011;306:2221–228.
Jeong YH, Lee SW, Choi BR, Kim IS, Seo MK, Kwak CH, et al. Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients with Clopidogrel Resistance) randomized study. J Am Coll Cardiol 2009;53:1101–1109.
Wallentin L, Varenhorst C, James S, Erlinge D, Braun OO, Jakubowski JA, et al. Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J 2008;29:21–30.
Ben-Dor I, Torguson R, Scheinowitz M, Li Y, Delhaye C, Wakabayashi K, et al. Incidence, correlates, and clinical impact of nuisance bleeding after antiplatelet therapy for patients with drug-eluting stents. Am Heart J 2010;159:871–875.
Sibbing D, Schulz S, Braun S, Morath T, Stegherr J, Mehilli J, et al. Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. J Thromb Haemost 2010;8:250–256.
Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357:2001–2015.
Lardizabal JA, Joshi BK, Ambrose JA. The balance between anti-ischemic efficacy and bleeding risk of antithrombotic therapy in percutaneous coronary intervention: a yin-yang paradigm. J Invasive Cardiol 2010;22:284–292.
Lau WC, Welch TD, Shields T, Rubenfire M, Tantry US, Gurbel PA. The effect of St John’s wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: increased platelet inhibition by enhancement of CYP3A4 metabolic activity. J Cardiovasc Pharmacol 2011;57:86–93.
Huang MW, Wang H, Zhong WJ, Wu XY, Chen H. Chinese herbal medicine Naoxintong capsule combined with dual antiplatelet therapy in a rat model of coronary microembolization induced by homologous microthrombi. J Chin Integr Med (Chin) 2011;9:38–48.
WANG H, Zhong WJ, Huang MW, Wu XY, Chen H. Efficacy of dual antiplatelet therapy combined with naoxintong capsules following coronary microembolization induced by homologous microthrombi in rats. Chin J Integr Med 2011;17:917–924.
Chen H, Yu G, Sun H, Wu X, Wang H. Comparison of adjunctive Naoxintong versus clopidogrel in volunteers with the CYP2C19 2 gene mutation accompanied with qi deficiency and blood stasis constitution. Evid Based Complement Alternat Med 2011; 2011:207034.
Born GVR. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962;194:927–929.
Kim KA, Park PW, Hong SJ, Park JY. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin Pharmacol Ther 2008;84:236–242.
Lau WC, Gurbel PA, Watkins PB, Neer CJ, Hopp AS, Carville DG, et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 2004;109:166–171.
Farid NA, Payne CD, Small DS, Winters KJ, Ernest CS 2nd, Brandt JT, et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther 2007;81:735–741.
Siller-Matula JM, Lang I, Christ G, Jilma B. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol 2008;52:1557–1563.
Sibbing D, Morath T, Stegherr J, Braun S, Vogt W, Hadamitzky M, et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 2009;101:714–719.
Gilard M, Arnaud B, Cornily JC, Le Gal G, Lacut K, Le Calvez G, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008;51:256–260.
Lau WC, Gurbel PA. The drug-drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009;180:699–700.
Charlot M, Ahlehoff O, Norgaard ML, Jørgensen CH, Sørensen R, Abildstrøm SZ, et al. Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study. Ann Intern Med 2010;153:378–386.
Zhu PL, Sun H, Wang SM, Zhuang J, Chen H, Wu XY, et al. Effect of proton pump inhibitors on clopidogrel resistance and recurrence of cardiovascular events in patients undergone percutaneous coronary intervention. J Clin Cardiol (Chin) 2012;15:518–521.
Wang LS, Zhu B, Abd El-Aty AM, Zhou G, Li Z, Wu J, et al. The influence of St John’s Wort on CYP2C19 activity with respect to genotype. J Clin Pharmacol 2004; 44:577–581.
Hellum BH, Hu Z, Nilsen OG. Trade herbal products and induction of CYP2C19 and CYP2E1 in cultured human hepatocytes. Basic Clin Pharmacol Toxicol 2009;105:58–63.
Fan L, Wang G, Wang LS, Chen Y, Zhang W, Huang YF, et al. Herbal medicine Yin Zhi Huang induces CYP3A4-mediated sulfoxidation and CYP2C19-dependent hydroxylation of omeprazole. Acta Pharmacol Sin 2007;28:1685–1692.
Wang LS, Zhou G, Zhu B, Wu J, Wang JG, Abd El-Aty AM, et al. St John’s wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole. Clin Pharmacol Ther 2004;75:191–197.
Yin OQ, Tomlinson B, Waye MM, Chow AH, Chow MS. Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole. Pharmacogenetics 2004;14:841–850.
Zhang H, Wang WR, Lin R, Zhang JY, Ji QL, Lin QQ, et al. Buyang Huanwu decoction ameliorates coronary heart disease with Qi deficiency and blood stasis syndrome by reducing CRP and CD40 in rats. J Ethnopharmacol 2010;130:98–102.
Chen H, Zhang Y, Wu X, Li C, Wang H. In vitro assessment of Cytochrome P450 2C 19 potential of Naoxintong. Evid Based Complement Alternat Med 2012;2012:430262.
0
浏览量
727
Downloads
11
CSCD
- Meta-XML下载
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
关联资源
相关文章
相关作者
相关机构
- 邮编：100091
- 联系电话：010-62886827, 62877592 传真：010-62874291
- 技术支持由北京北大方正电子有限公司提供 京ICP备05067934号-1
京公网安备11010802024621 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies
